Genovis Q1 2025: Inital take – solid quarter with sales beat - Redeye

Redeye shares its initial take on Genovis following the Q1 report, which delivered sales 13% above our estimates and an EBITDA margin of 28%, in line with our expectations. Enzyme sales reached their highest level to date, excluding license-related revenues while the share continue to trade at a slight premium to our bear case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1109269/genovis-q1-2025-inital-take-solid-quarter-with-sales-beat?utm_source=finwire&utm_medium=RSS